신경학 임상시험 시장 보고서(2025년)

Neurology clinical trials are research studies conducted to assess the safety, effectiveness, and outcomes of interventions like medications, therapies, or diagnostic methods for neurological conditions. These studies aim to improve treatments for disorders that impact the brain, spinal cord, and nervous system.

The primary stages of neurology clinical trials include Phase I, Phase II, Phase III, and Phase IV. Phase I is the initial stage, involving a small number of healthy individuals or patients, and focuses on evaluating a drug's safety, appropriate dosage range, and potential side effects. In the field of neurology, Phase I trials are particularly important for understanding how new treatments affect complex brain and nerve functions. The studies may follow different designs, such as interventional, observational, or expanded access. They address a variety of conditions, including epilepsy, Parkinson's disease (PD), Huntington's disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), muscle regeneration, and others. The primary users of these trials include hospitals, clinics, research centers, and related institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The neurology clinical trials market research report is one of a series of new reports from The Business Research Company that provides neurology clinical trials market statistics, including the neurology clinical trials industry's global market size, regional shares, competitors with the neurology clinical trials market share, detailed neurology clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the neurology clinical trials market. This neurology clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurology clinical trials market size has grown strongly in recent years. It will grow from $5.42 billion in 2024 to $5.80 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be credited to the rising prevalence of neurological disorders, growing demand for advanced treatment options, an increase in the aging population, greater investment in research and development by pharmaceutical companies, and improved awareness and diagnosis rates of neurological conditions.

The neurology clinical trials market size is expected to see strong growth in the next few years. It will grow to $7.54 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The projected growth in the forecast period can be attributed to the increasing adoption of precision medicine, a stronger focus on biomarker-driven studies, the rising application of artificial intelligence in trial design, a growing pipeline of neurology drugs, and enhanced government support and funding for neurological research. Key trends expected during this period include advancements in neuroimaging technologies, the use of advanced data analytics for patient stratification, the emergence of adaptive trial designs, innovations in wearable devices for neurological monitoring, and the development of decentralized clinical trial models.

The rising prevalence of neurological disorders is anticipated to drive the growth of the neurology clinical trials market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, or nerves, disrupting the normal functioning of the nervous system. This rise is largely linked to the aging population, as older adults are more prone to age-related conditions such as Alzheimer's and Parkinson's disease. Neurology clinical trials contribute to addressing these disorders by testing new treatments, drugs, or interventions that aim to improve diagnosis, manage symptoms, slow disease progression, and enhance patient outcomes. For example, in September 2024, the Australian Institute of Health and Welfare reported that the number of Australians living with dementia is projected to more than double, from 411,100 in 2023 to 849,300 by 2058. By that time, it is estimated that 315,500 men and 533,800 women will be living with the condition. This growing prevalence of neurological disorders is a key factor fueling the expansion of the neurology clinical trials market.

Leading companies in the neurology clinical trials sector are advancing treatment approaches through the development of innovative therapies such as monoclonal antibodies. These engineered molecules are designed to bind precisely to specific proteins or antigens, offering targeted treatment mechanisms that improve efficacy and speed up the development of novel therapies. For instance, in July 2024, Eli Lilly and Company, a U.S.-based pharmaceutical firm, introduced Kisunla (donanemab-azbt) for the treatment of early symptomatic Alzheimer's disease. This treatment helps slow cognitive and functional decline, giving eligible patients more time to maintain independence and engage in daily activities. Kisunla targets and reduces amyloid plaques in the brain, with clinical trial results indicating up to a 35% reduction in disease progression compared to a placebo in patients with less advanced Alzheimer's.

In March 2025, CLARIO, a U.S.-based healthcare company, acquired NeuroRx to enhance its neuroscience capabilities and support the advancement of neurology drug development. This strategic acquisition aims to strengthen CLARIO's position in medical imaging and expand its expertise in neurological research. NeuroRx, based in Canada, is a clinical-stage pharmaceutical company involved in conducting neurology clinical trials.

Major players in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, and Lindus Health Ltd.

North America was the largest region in the neurology clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurology clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurology clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurology clinical trials market consists of revenues earned by entities by providing services such as collecting and analyzing health data, monitoring patient safety, managing trial sites, regulatory consulting, and trial design and planning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurology Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurology clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurology clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurology clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Phase: Phase I; Phase II; Phase III; Phase IV
• 2) By Study Design: Interventional; Observational; Expanded Access
• 3) By Indication: Epilepsy; Parkinson's Disease (PD); Huntington's Disease; Stroke; Traumatic Brain Injury (TBI); Amyotrophic Lateral Sclerosis (ALS); Muscle Regeneration; Other Indications
• 4) By End-User: Hospitals; Clinics; Research Institutes; Other End- Users
• Subsegments:
• 1) By Phase I: Drug Safety Evaluation; Pharmacokinetics Assessment; Dosage Range Finding; Tolerability Studies
• 2) By Phase II: Efficacy Evaluation; Dose Response Studies; Therapeutic Effectiveness; Biomarker Identification
• 3) By Phase III: Large Scale Efficacy Studies; Safety Monitoring; Comparative Effectiveness; Risk Benefit Analysis
• 4) By Phase IV: Post Marketing Surveillance; Long Term Safety Follow Up; Real World Evidence Collection; Quality Of Life Assessment
• Companies Mentioned: AbbVie Inc.; Sanofi S.A.; Novartis AG; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; IQVIA Holdings Inc.; Biogen Inc.; ICON plc.; Syneos Health; Charles River Laboratories International Inc.; Parexel International Corporation; CMIC Holdings Co. Ltd.; Medpace Holdings Inc.; PSI CRO AG.; Supernus Pharmaceuticals Inc.; Worldwide Clinical Trials LLC.; Ergomed plc.; Biotrial S.A.S.; Clinilabs Drug Development Corporation; Lindus Health Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurology Clinical Trials Market Characteristics

3. Neurology Clinical Trials Market Trends And Strategies

4. Neurology Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurology Clinical Trials Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurology Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurology Clinical Trials Market Growth Rate Analysis
• 5.4. Global Neurology Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurology Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurology Clinical Trials Total Addressable Market (TAM)

6. Neurology Clinical Trials Market Segmentation

• 6.1. Global Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phase I
• Phase II
• Phase III
• Phase IV
• 6.2. Global Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interventional
• Observational
• Expanded Access
• 6.3. Global Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epilepsy
• Parkinson's Disease (PD)
• Huntington's Disease
• Stroke
• Traumatic Brain Injury (TBI)
• Amyotrophic Lateral Sclerosis (ALS)
• Muscle Regeneration
• Other Indications
• 6.4. Global Neurology Clinical Trials Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Institutes
• Other End- Users
• 6.5. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Safety Evaluation
• Pharmacokinetics Assessment
• Dosage Range Finding
• Tolerability Studies
• 6.6. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Efficacy Evaluation
• Dose Response Studies
• Therapeutic Effectiveness
• Biomarker Identification
• 6.7. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Large Scale Efficacy Studies
• Safety Monitoring
• Comparative Effectiveness
• Risk Benefit Analysis
• 6.8. Global Neurology Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Post Marketing Surveillance
• Long Term Safety Follow Up
• Real World Evidence Collection
• Quality Of Life Assessment

7. Neurology Clinical Trials Market Regional And Country Analysis

• 7.1. Global Neurology Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurology Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurology Clinical Trials Market

• 8.1. Asia-Pacific Neurology Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurology Clinical Trials Market

• 9.1. China Neurology Clinical Trials Market Overview
• 9.2. China Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurology Clinical Trials Market

• 10.1. India Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurology Clinical Trials Market

• 11.1. Japan Neurology Clinical Trials Market Overview
• 11.2. Japan Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurology Clinical Trials Market

• 12.1. Australia Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurology Clinical Trials Market

• 13.1. Indonesia Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurology Clinical Trials Market

• 14.1. South Korea Neurology Clinical Trials Market Overview
• 14.2. South Korea Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurology Clinical Trials Market

• 15.1. Western Europe Neurology Clinical Trials Market Overview
• 15.2. Western Europe Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurology Clinical Trials Market

• 16.1. UK Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurology Clinical Trials Market

• 17.1. Germany Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurology Clinical Trials Market

• 18.1. France Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurology Clinical Trials Market

• 19.1. Italy Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurology Clinical Trials Market

• 20.1. Spain Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurology Clinical Trials Market

• 21.1. Eastern Europe Neurology Clinical Trials Market Overview
• 21.2. Eastern Europe Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurology Clinical Trials Market

• 22.1. Russia Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurology Clinical Trials Market

• 23.1. North America Neurology Clinical Trials Market Overview
• 23.2. North America Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurology Clinical Trials Market

• 24.1. USA Neurology Clinical Trials Market Overview
• 24.2. USA Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurology Clinical Trials Market

• 25.1. Canada Neurology Clinical Trials Market Overview
• 25.2. Canada Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurology Clinical Trials Market

• 26.1. South America Neurology Clinical Trials Market Overview
• 26.2. South America Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurology Clinical Trials Market

• 27.1. Brazil Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurology Clinical Trials Market

• 28.1. Middle East Neurology Clinical Trials Market Overview
• 28.2. Middle East Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurology Clinical Trials Market

• 29.1. Africa Neurology Clinical Trials Market Overview
• 29.2. Africa Neurology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurology Clinical Trials Market Competitive Landscape And Company Profiles

• 30.1. Neurology Clinical Trials Market Competitive Landscape
• 30.2. Neurology Clinical Trials Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Neurology Clinical Trials Market Other Major And Innovative Companies

• 31.1. IQVIA Holdings Inc.
• 31.2. Biogen Inc.
• 31.3. ICON plc.
• 31.4. Syneos Health
• 31.5. Charles River Laboratories International Inc.
• 31.6. Parexel International Corporation
• 31.7. CMIC Holdings Co. Ltd.
• 31.8. Medpace Holdings Inc.
• 31.9. PSI CRO AG.
• 31.10. Supernus Pharmaceuticals Inc.
• 31.11. Worldwide Clinical Trials LLC.
• 31.12. Ergomed plc.
• 31.13. Biotrial S.A.S.
• 31.14. Clinilabs Drug Development Corporation
• 31.15. Lindus Health Ltd.

32. Global Neurology Clinical Trials Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurology Clinical Trials Market

34. Recent Developments In The Neurology Clinical Trials Market

35. Neurology Clinical Trials Market High Potential Countries, Segments and Strategies

• 35.1 Neurology Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurology Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurology Clinical Trials Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer